Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison M Schram

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Nature|February 9, 2018
HER kinase inhibition in patients with HER2- and HER3-mutant cancersDavid M Hyman, Sarina A Piha-Paul, Helen Won, et al.
Cancer Discovery|November 2, 2023
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from HyperinsulinemiaAndreas Varkaris, Ermira Pazolli, Hakan Gunaydin, et al.
Cancer Discovery|December 7, 2019
Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast CancerLillian M Smyth, Sarina A Piha-Paul, Helen H Won, et al.
Nature Medicine|May 9, 2017
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsAhmet Zehir, Ryma Benayed, Ronak H Shah, et al.
Nature Medicine|August 5, 2017
Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsAhmet Zehir, Ryma Benayed, Ronak H Shah, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Nature|February 9, 2018
HER kinase inhibition in patients with HER2- and HER3-mutant cancersDavid M Hyman, Sarina A Piha-Paul, Helen Won, et al.
Cancer Discovery|November 2, 2023
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from HyperinsulinemiaAndreas Varkaris, Ermira Pazolli, Hakan Gunaydin, et al.
Cancer Discovery|December 7, 2019
Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast CancerLillian M Smyth, Sarina A Piha-Paul, Helen H Won, et al.
Nature Medicine|May 9, 2017
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsAhmet Zehir, Ryma Benayed, Ronak H Shah, et al.
Nature Medicine|August 5, 2017
Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsAhmet Zehir, Ryma Benayed, Ronak H Shah, et al.
Pageof 8